Alyssa Morgan

Articles by Alyssa Morgan

141 DESTINY-Breast06 Post Hoc Analysis by Physician’s Choice of Chemotherapy: Efficacy and Safety of Trastuzumab Deruxtecan Versus Physician’s Choice of Chemotherapy in Hormone Receptor–Positive, HER2-Low or -Ultralow Metastatic Breast Cancer

ByCarlos H Barrios,Aditya Bardia, MD, MPH, FASCO,Xichun Hu,Rebecca Dent, MD,Kan Yonemori,Alyssa Morgan,Giuseppe Curigliano

April 30th 2026

142 Exploratory Biomarker Analysis of Trastuzumab Deruxtecan Versus Physician’s Choice of Chemotherapy in HER2-Low/Ultralow, Hormone Receptor–Positive Metastatic Breast Cancer in DESTINY-Breast06

ByRebecca Dent, MD,Giuseppe Curigliano,Xichun Hu,Kan Yonemori,Carlos H Barrios,Alyssa Morgan,Aditya Bardia, MD, MPH, FASCO

April 30th 2026

Latest Updated Articles

Trending on CancerNetwork

CD38-Targeted Immuno-PET Helps Detect Active Multiple Myeloma

Biomarker Sequencing, PD-L1 Status, and FLOT Dosing in Gastroesophageal Cancer

Setting Up an HDR Brachytherapy Program Amid a National Decline

Zamto-Cel Improves EFS vs R-GemOx in Transplant-Ineligible R/R LBCL

16-Fraction PMRT With IMN Irradiation Noninferior in High-Risk Breast Cancer